drugset

drugset / Trial / NCT00333034

Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis

NCT00333034 ↗

Phase 3 Completed 120 enrolled Wyeth is now a wholly owned subsidiary of Pfizer Amgen · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to assess the efficacy and safety of etanercept 50 mg administered once weekly in subjects with psoriasis over 12 weeks.

Timeline

Start: 2006-06
Primary completion: —
Completion: 2007-05

Publications

Griffiths CE, Christophers E, Szumski A, Jones H, Mallbris L. Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis. Br J Dermatol. 2015 Nov;173(5):1271-3. doi: 10.1111/bjd.13865. Epub 2015 Aug 17. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etanercept	Protein / enzyme biologic	50 mg	—

Indications